Available technologies, Life Sciences, Pharmaceuticals


The beneficial effects of medium-chain triglycerides (MCT) is now scientifically demonstrated.  They present curative potential for obesity, glucose tolerance and insulin sensitivity.

Obesity: An important public health problem

  • 2.1 billion people are obese or overweight
  • 40% of American adults are obese
  • Consequences include CV diseases, diabetes, musculoskeletal disorders and cancers
  • Economic burden of $344 billion in US (2018)

Medium-chain triglycerides (MCT) enriched diet presents curative potential for metabolic diseases

  • Obesity results from diet abnormally rich in carbohydrates and long chain saturated fatty acids, potent inducers of lipogenesis and triglyceride accumulation in the liver
  • The proof-of-concept for MCT benefits in metabolic health has been demonstrated in obese mice:
    • Induction of weight loss
    • Rescue of glucose tolerance
    • Reduction of hepatic mass
    • Improvement of insulin sensitivity
    • Rescue of hepatic AKT phosphorylation

MCT presents multiple advantages compared to omega-3

  • Obtained from renewable, non-declining source
  • No taste issues for consumers
  • Higher digestibility
  • Higher solubility in water
  • Quickly metabolized and converted into a readily available source of energy

Multiple applications for MCT in food and beverages industry

  • Dietary supplement
  • Ingredient for functional food
  • Energy drinks without caffeine or high sugar content
  • Market: Omega-3 food and beverage market is expected to $62.3 billion in 2023

In-licensing opportunity

  • MCT are molecules with GRAS (generally recognized as safe) status from FDA
  • Business opportunity to obtain health claims associated to MCT benefits
  • Patent: PCT CA2017051463


If you are interested by this technology, please contact :

Christine Martens, Principal Director Business Development, Life Sciences
cmartens@aligo.ca, (514) 840-1226, Ext. 3008


Université du Québec à Montréal (UQAM)


Catherine Mounier

Dr Catherine Mounier
Professor, Biological Sciences

Dr Catherine Mounier is Vice-President Research of Université du Québec à Montréal (UQAM) since July 2015. Dr Mounier obtained her B.Sc. in Biochemistry (1987) and her M.Sc. in Molecular Chemistry (1988) from Rennes University (France). She then obtained her Ph.D. in Cellular and Molecular Biology (1994) at the National Superior Agronomic school in Rennes (France). Dr Mounier then continued her investigations through a postdoctoral training at Iowa University (USA) and McGill University. Dr Mounier is professor at the Biological Sciences Department of UQAM since 2003. She acted as Director from 2012 to 2015. Her research projects focus on lipid metabolism and insulin sensitivity in relationship to cancer and neurodegenerative diseases.